ArticleCureus2025
Clinical Characteristics and Outcomes of Nontuberculous Mycobacterial Empyema.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction The incidence of pulmonary nontuberculous mycobacterial (NTM) infections has increased in recent decades. But NTM empyema is still a rare disease. The purpose of this study was to clarify the clinical characteristics and outcomes of NTM empyema. Methods The medical records of 484 patients with pulmonary NTM disease (NTM empyema 15, NTM disease without empyema 469) and 367 patients with acute empyema (NTM empyema 15, other empyema 352) were retrospectively reviewed and investigated patients with empyema with other causes as well as patients with NTM empyema from January 2012 to December 2024 in our hospital. NTM empyema was defined as a positive NTM culture of pleural effusion samples and had purulent pleural effusion. Results Among patients with pulmonary NTM and patients with acute empyema in our study, 15 had NTM empyema (3.1%, 4.1%). Age (median 78 vs. 68, p=0.0072), male (60.0% vs. 32.4%, p=0.0256), Charlson Comorbidity Index (CCI, median 6 vs. 4, p=0.0007) and fibrocavitary form patients (60.0% vs. 21.5%, p=0.0005) were higher in the NTM empyema than in the NTM disease without empyema. Although the same long-term follow-up as NTM disease without empyema was performed, the long-term prognosis of NTM empyema was poorer than that of NTM disease without empyema. Ten out of 15 patients with NTM empyema and 52 out of 352 patients with other empyema patients were complicated with pneumothorax. Compared to patients with other empyema, patients with NTM empyema had higher incidences of pneumothorax (66.7% vs. 14.8%, p=0.00001). Surgical treatments were performed for 11 patients of 15 NTM empyema - two patients died (18.2%) - and were more frequently performed for other empyema. There were significant differences between the mortality rate for fistulous patients with NTM empyema and those for fistulous patients with other empyema (40.0% vs. 11.5%, p=0.0250). All patients with NTM empyema who died had pneumothorax. No fistulous patient with NTM empyema was cured without surgical treatment. Conclusions NTM empyema patients had higher rates of fibrocavitary form, were male, and had higher CCI, and the long-term prognosis of NTM empyema was poorer than that of NTM disease without empyema. In addition, this study revealed that NTM empyema has a poor prognosis and is difficult to treat without chest tube drainage or surgical treatment. Early surgical intervention should be considered for patients with fistulous NTM empyema.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.